Rationale and design of MARQUEE: A phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer

Giorgio V. Scagliotti, Silvia Novello, Joan H. Schiller, Vera Hirsh, Lecia V. Sequist, Jean Charles Soria, Joachim Von Pawel, Brian Schwartz, Reinhard Von Roemeling, Alan B. Sandler

Research output: Contribution to journalArticlepeer-review

123 Scopus citations

Fingerprint

Dive into the research topics of 'Rationale and design of MARQUEE: A phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences